Global Amitriptyline Market Size, Share, Growth, Trends and Forecast (2021-2027)

Global Amitriptyline Market is expected to grow significantly by 2027 expanding at a reasonable CAGR of around 6% during the forecast period (2021-2027). Amitriptyline is a drug that affects certain chemical messengers (neurotransmitters) which communicate between the cells of the brain and help in regulating mood. It is a tricyclic antidepressant that is used in the treatment of various health conditions such as chronic neuropathic pain, depression, migraine, and others.

Access sample report (including graphs, charts, and figures): https://univdatos.com/get-a-free-sample-form-php/?product_id=17401

The amitriptyline market is expected to witness an uptick across the globe owing to the rising investment by various pharmaceutical countries and the growing prevalence of neuropathic pain among the U.S. population. For instance, in 2018, the reported prevalence of neuropathic pain in the U.S. was 10%, according to a study published in the Journal of pain research. Also, almost 20 million Americans have some type of peripheral neuropathy, as reported by the National Institute of Neurological Disorders and Stroke. Furthermore, the growing healthcare expenditure and rise in research and development of drugs in various pharmaceutical companies are also some of the prominent factors contributing to the growth of the market.

Based on strength, the market is segmented into 10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg tablets, 100 mg tablets, and 150 mg tablets. The 10 mg tablets segment grabbed an XX% share of the global amitriptyline market and will witness a considerable CAGR of XX% during the forecast period (2021-2027F) owing to the frequent product launch and wide availability of low strength tablets in the market.

Based on the indication, the global amitriptyline market is segmented into depression, migraine, nocturnal enuresis, chronic neuropathic pain, and others. Chronic neuropathic pain occupied a substantial share and is expected to grow at a CAGR of XX% during the forecast period 2021-2027 owing to an increase in the number of people affected by this disease globally.

For a detailed analysis of the amitriptyline browse through https://univdatos.com/report/amitriptyline-market/

Additionally, the report provides detailed report also provides insights into the global amitriptyline market according to the regions such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America dominated the market and generated revenue of USD XX billion in 2020 owing to the well-established market players and frequent product launches.

Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries, Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson Laboratories Inc., Torrent Pharmaceuticals Ltd., are some of the key players operating in the global amitriptyline market. Several M&As along with partnerships have been undertaken by these players to develop new products.

Global Amitriptyline Market Segmentation

Market Insight, by Strength

· 10 mg tablets

· 25 mg tablets

· 50 mg tablets

· 75 mg tablets

· 100 mg tablets

· 150 mg tablets

Market Insight, by Indication

· Depression

· Migraine

· Nocturnal Enuresis